614 McKinley Place N.E.
143 articles with Bio-Techne
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
Bio-Techne has further added to its cell therapy portfolio by expanding the range of Tocris Bioscience-branded cGMP small molecules to include the commonly used stem cell compounds, Y-27632 (ROCK inhibitor) and CHIR 99021.
Bio-Techne Corporation today announced that Dave Eansor, President Protein Sciences will present at the Citi 2018 Global Healthcare Conference on Wednesday, December 5, 2018, at 2:10 p.m. EST.
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2018.
Bio-Techne Corporation today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2018 Stephens NY Investment Conference on Wednesday, November 7, 2018, at 10:30 a.m. EST.
Bio-Techne has entered into a strategic cooperation agreement with Micropoint Bioscience of Shenzhen, China.
Bio-Techne is proud to announce that one of its Principal Scientists, Jiaqi Wu, Ph.D., was presented with the CE Pharm Award at this year's CE Pharm meeting, September 9-12, 2018, for his contributions to the capillary electrophoresis (CE) field.
Bio-Techne has announced a corporate initiative to advance cell and gene therapy research and ex vivo cell processing.
Bio-Techne Announces Publication of Data Demonstrating Additional Clinical Validation of its EPI Test in European Urology Journal
Bio-Techne today announced the online publication of its second prospective US clinical validation study of the Exosome Diagnostics-branded ExoDx® Prostate(IntelliScore) (EPI)
Bio-Techne researchers publish papers that promise to open the field of glycobiology to the masses.
Bio-Techne Corporation today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018, at 8:00 a.m. EDT.
Bio-Techne Corporation today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Baird 2018 Global Healthcare Conference on Thursday, September 6, 2018, at 9:40 a.m. EDT.
Bio-Techne has introduced a new range of Tocris Bioscience-branded stem cell research compounds produced to cGMP standards, which are suitable for use as ancillary materials in the development of stem cell therapies.
Bio-Techne Corporation reported its financial results for the fourth quarter ended June 30, 2018.
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2018.
Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its acquisition of Exosome Diagnostics, Inc.
Bio-Techne again disrupts protein analysis technology with the introduction of the newest member of their ProteinSimple-branded Simple Western family, Jess.
Bio-Techne To Host Conference Call On August 7, 2018 To Announce Fourth Quarter 2018 Financial Results
Bio-Techne Corporation announced that management will host a conference call on Tuesday, August 7, 2018 at 8:00 a.m. CDT to review fourth quarter 2018 financial results.
Bio-Techne Scales Antibody Validation Initiative Using CRISPR Gene Editing Technology Across a Broad Spectrum of Targets
Knockout Validation of Antibodies Confirms Specificity and Ensures Reproducible Results
Validated tissue bank and pre-collected immuno-oncology datasets speed up investigative research projects through to clinical development...